Secures consecutive orders following Phase 1; production and regulatory support to be handled at Osong GMP facility.
Ensuring quality consistency through standardized manufacturing processes; expanding supply across drug development stages.
HLB Pept, a company specializing in peptides, has expanded its contract development and manufacturing organization (CDMO) business by signing a supply agreement for active pharmaceutical ingredients (API) for Skinmed's Phase 2 clinical trials. By securing consecutive orders from Phase 1 through to the subsequent stage, the company has gained recognition for its production and quality control capabilities.
According to HLB Pept on the 20th, the company won the CDMO contract for 'SMD-101' (generic name: Aripeptide), a peptide drug candidate developed by skin life science firm Skinmed.
HLB Pept plans to produce the materials at its Osong GMP facility using the same manufacturing process employed during the Phase 1 trials. This approach ensures consistency in material quality despite the transition between clinical stages.
Furthermore, the company will conduct analytical method validation, long-term stability testing, and stress testing. HLB Pept will also prepare the API section of the Common Technical Document (CTD) required for drug approval and provide support for any supplementary requests arising during the Ministry of Food and Drug Safety's review of the Phase 2 clinical trial application.
Consecutive Orders Strengthen CDMO Competitiveness
Aripeptide is a peptide drug candidate currently being developed by Skinmed for the treatment of focal muscle relaxation. Skinmed received approval for its Phase 1 Investigational New Drug (IND) application from the Ministry of Food and Drug Safety last May.
This contract is significant as it demonstrates HLB Pept's ability to maintain supply continuity from the early stages of drug development. It serves as a testament to the company's CDMO competitiveness, highlighting its capacity to provide both consistent manufacturing and comprehensive regulatory documentation support.
Shim Kyung-jae, CEO of HLB Pept, stated, "Securing the Phase 2 supply contract following our work on Phase 1 is a result of the trust we have built through our production and quality management. We will take full responsibility for material production and regulatory preparation to ensure Skinmed's clinical schedule proceeds without disruption."
Meanwhile, HLB Pept announced on the 10th that a finished drug product using its Leuprorelin API received marketing authorization in Mexico. On the 17th, the company appointed Lee Won-jik, former CEO of Lotte Biologics, as its new president to accelerate the expansion of its global peptide API business.
Currently, HLB Pept supplies peptide APIs such as Leuprorelin, Desmopressin, and Vasopressin, while actively expanding its CDMO services for pharmaceutical developers.







